vs

Side-by-side financial comparison of Bridgewater Bancshares Inc (BWB) and Cytek Biosciences, Inc. (CTKB). Click either name above to swap in a different company.

Cytek Biosciences, Inc. is the larger business by last-quarter revenue ($62.1M vs $46.2M, roughly 1.3× Bridgewater Bancshares Inc). Bridgewater Bancshares Inc runs the higher net margin — 37.7% vs -70.9%, a 108.6% gap on every dollar of revenue. Over the past eight quarters, Bridgewater Bancshares Inc's revenue compounded faster (31.4% CAGR vs 17.7%).

Bridgewater Bancshares Inc. is a regional bank holding company headquartered in Minnesota, U.S. It offers a full suite of commercial and retail banking services including business loans, deposit products, residential mortgages, and personal banking solutions, primarily serving SMEs, individual consumers and local commercial clients in its operating areas.

Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.

BWB vs CTKB — Head-to-Head

Bigger by revenue
CTKB
CTKB
1.3× larger
CTKB
$62.1M
$46.2M
BWB
Higher net margin
BWB
BWB
108.6% more per $
BWB
37.7%
-70.9%
CTKB
Faster 2-yr revenue CAGR
BWB
BWB
Annualised
BWB
31.4%
17.7%
CTKB

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BWB
BWB
CTKB
CTKB
Revenue
$46.2M
$62.1M
Net Profit
$17.4M
$-44.1M
Gross Margin
52.9%
Operating Margin
-9.0%
Net Margin
37.7%
-70.9%
Revenue YoY
8.1%
Net Profit YoY
80.7%
-557.1%
EPS (diluted)
$0.58

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BWB
BWB
CTKB
CTKB
Q1 26
$46.2M
Q4 25
$38.8M
$62.1M
Q3 25
$36.2M
$52.3M
Q2 25
$36.1M
$45.6M
Q1 25
$32.3M
$41.5M
Q4 24
$29.5M
$57.5M
Q3 24
$27.1M
$51.5M
Q2 24
$26.8M
$46.6M
Net Profit
BWB
BWB
CTKB
CTKB
Q1 26
$17.4M
Q4 25
$13.3M
$-44.1M
Q3 25
$11.6M
$-5.5M
Q2 25
$11.5M
$-5.6M
Q1 25
$9.6M
$-11.4M
Q4 24
$8.2M
$9.6M
Q3 24
$8.7M
$941.0K
Q2 24
$8.1M
$-10.4M
Gross Margin
BWB
BWB
CTKB
CTKB
Q1 26
Q4 25
52.9%
Q3 25
52.7%
Q2 25
52.3%
Q1 25
48.6%
Q4 24
58.5%
Q3 24
56.3%
Q2 24
54.6%
Operating Margin
BWB
BWB
CTKB
CTKB
Q1 26
Q4 25
44.2%
-9.0%
Q3 25
41.8%
-17.6%
Q2 25
42.0%
-23.3%
Q1 25
39.2%
-36.1%
Q4 24
35.6%
5.2%
Q3 24
41.9%
-8.2%
Q2 24
39.7%
-18.3%
Net Margin
BWB
BWB
CTKB
CTKB
Q1 26
37.7%
Q4 25
34.3%
-70.9%
Q3 25
32.1%
-10.5%
Q2 25
31.9%
-12.2%
Q1 25
29.8%
-27.5%
Q4 24
27.8%
16.8%
Q3 24
32.0%
1.8%
Q2 24
30.3%
-22.4%
EPS (diluted)
BWB
BWB
CTKB
CTKB
Q1 26
$0.58
Q4 25
$0.42
Q3 25
$0.38
Q2 25
$0.38
Q1 25
$0.31
Q4 24
$0.26
Q3 24
$0.27
Q2 24
$0.26

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BWB
BWB
CTKB
CTKB
Cash + ST InvestmentsLiquidity on hand
$222.2M
$90.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$528.4M
$341.7M
Total Assets
$5.3B
$461.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BWB
BWB
CTKB
CTKB
Q1 26
$222.2M
Q4 25
$123.5M
$90.9M
Q3 25
$131.8M
$93.3M
Q2 25
$217.5M
$75.5M
Q1 25
$166.2M
$95.3M
Q4 24
$229.8M
$98.7M
Q3 24
$191.9M
$162.3M
Q2 24
$134.1M
$177.9M
Stockholders' Equity
BWB
BWB
CTKB
CTKB
Q1 26
$528.4M
Q4 25
$517.1M
$341.7M
Q3 25
$497.5M
$378.6M
Q2 25
$476.3M
$377.6M
Q1 25
$469.0M
$379.6M
Q4 24
$457.9M
$395.7M
Q3 24
$452.2M
$385.5M
Q2 24
$439.2M
$389.1M
Total Assets
BWB
BWB
CTKB
CTKB
Q1 26
$5.3B
Q4 25
$5.4B
$461.5M
Q3 25
$5.4B
$494.9M
Q2 25
$5.3B
$493.3M
Q1 25
$5.1B
$482.6M
Q4 24
$5.1B
$499.5M
Q3 24
$4.7B
$491.2M
Q2 24
$4.7B
$483.7M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BWB
BWB
CTKB
CTKB
Operating Cash FlowLast quarter
$-771.0K
Free Cash FlowOCF − Capex
$-1.8M
FCF MarginFCF / Revenue
-2.9%
Capex IntensityCapex / Revenue
1.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-8.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BWB
BWB
CTKB
CTKB
Q1 26
Q4 25
$27.8M
$-771.0K
Q3 25
$9.4M
$-3.9M
Q2 25
$4.0M
$108.0K
Q1 25
$7.5M
$-125.0K
Q4 24
$46.4M
$2.0M
Q3 24
$-6.0M
$13.2M
Q2 24
$10.6M
$6.2M
Free Cash Flow
BWB
BWB
CTKB
CTKB
Q1 26
Q4 25
$22.0M
$-1.8M
Q3 25
$7.8M
$-4.6M
Q2 25
$2.8M
$-1.5M
Q1 25
$6.9M
$-974.0K
Q4 24
$42.3M
$1.1M
Q3 24
$-6.5M
$12.2M
Q2 24
$10.4M
$5.2M
FCF Margin
BWB
BWB
CTKB
CTKB
Q1 26
Q4 25
56.6%
-2.9%
Q3 25
21.5%
-8.7%
Q2 25
7.8%
-3.2%
Q1 25
21.5%
-2.3%
Q4 24
143.4%
1.9%
Q3 24
-23.8%
23.7%
Q2 24
38.9%
11.0%
Capex Intensity
BWB
BWB
CTKB
CTKB
Q1 26
Q4 25
15.1%
1.6%
Q3 25
4.4%
1.3%
Q2 25
3.2%
3.5%
Q1 25
1.7%
2.0%
Q4 24
13.8%
1.6%
Q3 24
1.7%
2.0%
Q2 24
0.7%
2.3%
Cash Conversion
BWB
BWB
CTKB
CTKB
Q1 26
Q4 25
2.09×
Q3 25
0.81×
Q2 25
0.35×
Q1 25
0.77×
Q4 24
5.65×
0.21×
Q3 24
-0.69×
14.05×
Q2 24
1.31×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BWB
BWB

Net Interest Income$36.6M79%
Noninterest Income$9.6M21%

CTKB
CTKB

Products$46.6M75%
Services$15.5M25%

Related Comparisons